Last reviewed · How we verify
IK-3001
IK-3001 is an intravenous iron replacement therapy that replenishes depleted iron stores in patients with iron deficiency.
IK-3001 is an intravenous iron replacement therapy that replenishes depleted iron stores in patients with iron deficiency. Used for Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or with inadequate response to oral iron.
At a glance
| Generic name | IK-3001 |
|---|---|
| Also known as | inhaled nitric oxide |
| Sponsor | Mallinckrodt |
| Drug class | Intravenous iron replacement agent |
| Target | Iron (Fe3+) delivery system |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
IK-3001 is a ferric carboxymaltose complex designed to deliver iron intravenously for rapid repletion of iron stores in iron deficiency anemia. The drug allows for high-dose iron administration in a single or limited number of infusions, bypassing gastrointestinal absorption limitations and improving patient compliance compared to oral iron supplementation.
Approved indications
- Iron deficiency anemia in patients with chronic kidney disease
- Iron deficiency anemia in patients intolerant to or with inadequate response to oral iron
Common side effects
- Injection site reactions
- Hypophosphatemia
- Headache
- Nausea
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IK-3001 CI brief — competitive landscape report
- IK-3001 updates RSS · CI watch RSS
- Mallinckrodt portfolio CI